MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variantsopen access
- Authors
- Lee, S.; Jang, S.; Kang, J.; Park, S.B.; Han, Y.W.; Nam, H.; Kim, M.; Lee, J.; Cho, K.J.; Kim, J.; Oh, M.; Ryu, J.; Seok, J.H.; Kim, Y.; Lee, J.-B.; Park, M.-S.; Kim, Y.-S.; Park, H.; Kim, D.-S.
- Issue Date
- Nov-2021
- Publisher
- Frontiers Media S.A.
- Keywords
- MG1141A; monoclonal antibody; outbreak; SARS-CoV-2; spike protein
- Citation
- Frontiers in Immunology, v.12
- Indexed
- SCIE
SCOPUS
- Journal Title
- Frontiers in Immunology
- Volume
- 12
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/62828
- DOI
- 10.3389/fimmu.2021.778829
- ISSN
- 1664-3224
1664-3224
- Abstract
- Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC50 of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations. Copyright © 2021 Lee, Jang, Kang, Park, Han, Nam, Kim, Lee, Cho, Kim, Oh, Ryu, Seok, Kim, Lee, Park, Kim, Park and Kim.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 1. Basic Science > Department of Microbiology > 1. Journal Articles
- 4. Research institute > Institute for Viral Diseases > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.